A selective TNKS2 inhibitor for tumor-restricted WNT suppression.
Hyperactive WNT signaling is a potent cancer driver but clinical translation of WNT inhibitors has been hampered by on-target toxicities. WNT signaling can be constrained through inhibition of the PARP-family enzymes tankyrase 1 (TNKS1) and TNKS2; however, existing TNKS inhibitors suppress WNT signaling in both tumor a...